Setting the record straight: The office of technology assessment report—pharmaceutical R&D costs, risks, and rewards
✍ Scribed by Alice M. Sapienza
- Publisher
- John Wiley and Sons
- Year
- 1993
- Tongue
- English
- Weight
- 617 KB
- Volume
- 30
- Category
- Article
- ISSN
- 0272-4391
No coin nor oath required. For personal study only.
✦ Synopsis
The U.S. Office of Technology Assessment (OTA) report on pharmaceutical research and development ( R & D ) s o s t s , risks, rewards-has generated a range of often heated responses, both for and against the industry. The purpose of this commentary is t o clarify two points of confusion that repeatedly appear about the report: First, it i s not a new and definitive study of the cost of pharmaceutical R&D (although certain related studies were commissioned by OTA). Second, the report i s not unexpected, given the political-economic context in which drug prices have historically been discussed. o 1993 WiIey-Liss, Inc.